Info

Synta Pharmaceuticals Corp. is a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to extend and enhance the lives of patients with severe medical conditions, including cancer and chronic inflammatory diseases. The Company has three drug candidates in clinical trials, one drug candidate in preclinical studies, and one program undergoing lead optimization. Its lead candidate is elesclomol an injectable, small molecule compound that triggers apoptosis, or programmed cell death, in cancer cells. The Company's other drug candidates are STA-9090 and STA-9584 for cancer treatment, and Apilimod (STA-5326) and CRAC ion channel inhibitor for autoimmune and inflammatory diseases.(Source: 10-K)